Navigation Links
Updated: Teikoku Pharma USA, Inc. and Verde Environmental Technologies, Inc. Announce Licensing Agreement for Pharmaceutical Disposal Technology
Date:9/15/2011

SAN JOSE, Calif., Sept. 15, 2011 /PRNewswire/ -- Teikoku Pharma USA, Inc., ("TPU") is pleased to announce an exclusive license agreement with Verde Environmental Technologies Inc. ("Verde"), a company aimed at developing environmentally responsible solutions for pharmaceutical disposal.  Verde is a privately held company, founded by former executives of TPU and Travanti Pharma, Inc.

Verde obtained rights to develop products, which are designed to adsorb and inactivate the active ingredients in pills, tablets, capsules and topical patches, in a convenient and environmentally responsible manner, based on patented technology developed and owned by TPU.  

"We are very pleased that these new product ideas that were generated from our research led to this important new development, stated TPU CEO, Masahisa Kitagawa.  TPU located in San Jose, California is the US operations of Teikoku Seiyaku Co., Ltd., one of the world's largest manufacturers of medicated patches based in Japan, and its product, Lidoderm, is a leading global brand.

"The products being developed by Verde will address the growing issue of pharmaceutical contamination of groundwater supplies.  By providing an effective means of adsorbing the active ingredients, this will help keep waste pharmaceuticals from appearing in the water supply," stated Verde Chairman and CEO, Dr. Andrew Korey.  "In addition, these developments will provide anti-abuse features, and improved safety, by diminishing the risk of accidental poisoning from active pharmaceuticals disposed in trash."

About Teikoku

Teikoku Pharma USA Inc., a wholly-owned subsidiary of Teikoku Seiyaku Inc. of Japan, is a specialty pharmaceutical company that develops, and manufactures enhanced pharmaceutical products based on its transdermal drug delivery technologies. Teikoku focuses its efforts in two therapeutic areas; Pain Management and CNS. Teikoku's main product is Lidoderm® (Lidocaine 5% Patch) for PHN, in collaboration with Endo Pharmaceuticals in the US, Grunenthal GmbH in Europe, Mundipharma in South East Asia and SK Pharma for Korea.

For more information about Teikoku Pharma USA, Inc. please visit http://www.teikokuusa.com.

Or

Contact: Francisco Bejar
Director, Business Development
408-501-1804
fbejar@teikokuusa.com

About Verde

Verde Environmental Technologies Inc. is a company aimed at developing environmentally responsible solutions for the growing issues related to pharmaceutical disposal.  Products for pharmaceutical manufacturers, pharmacies, and consumers will incorporate carbon adsorptive technologies to inactivate residual active pharmaceutical ingredients in tablets, capsules, patches, etc., and make them safe for disposal in an environmentally responsible manner. Verde operations are based in Minnesota and California.

For more information about Verde environmental Technologies, Inc. please visit http://www.verdeenvirotech.com.

Or

Contact: Andrew Korey
Ph.D. CEO/Chairman
akorey@verdeenvirotech.com


'/>"/>
SOURCE Teikoku Pharma USA, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. UPDATED: Elsevier Online Opinion Survey Reveals Researchers Ready to Push Scientific Search and Discovery to the Next Level
2. Licensing Agreement for Pharmaceutical Disposal Technology Between Teikoku Pharma USA, Inc. and Verde Environmental Technologies Inc.
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... OAKS, Calif. , April 19, 2017 /PRNewswire/ ... industrial buildings it is developing at Conejo Spectrum ... , to Atara Biotherapeutics, Inc. , ... with severe and life-threatening diseases that have been ... on allogeneic T-cell therapies for cancer, autoimmune and ...
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, Inc. ... providing the Urology, Uro/Gyn and Gynecology markets with innovative ... first quarter ended March 31, 2017 after the market ... The Company will host a conference call and webcast ... Tuesday, May 2, 2017 at 4:30 p.m. Eastern Time ...
(Date:4/18/2017)... April 18, 2017 Research and Markets has ... report to their offering. ... The global arthroscopy devices market to grow at a CAGR of ... Arthroscopy Devices Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... , ... Lake Park Dental is now accepting new patients with crooked teeth ... With the help of this highly-effective, yet convenient system, patients can straighten their teeth ... less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear and Elizabeth Dy, ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... unveiling cutting-edge birth defects research related to Zika virus during pregnancy, as well ... society for this important science. , The Teratology Society is ...
(Date:4/25/2017)... , ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing ... acute or chronic problems, I focus on preventative care with all my patients to alleviate ... any questions, always feel free to contact my office and my trained staff will assist ...
(Date:4/25/2017)... ... 25, 2017 , ... There is no better place in South Florida to ... in the May issue of Consumer Reports focused on heart health. , The ... during and after coronary bypass and aortic valve replacement procedures. , Consumer Reports ...
(Date:4/24/2017)... ... , ... Emmanuel College is introducing enhancements to its RN-to-BSN ... the fall of 2017, Emmanuel’s program will allow registered nurses (RN)s to earn a ... for as little as $14,528. These changes will enable nurses to complete their degree ...
Breaking Medicine News(10 mins):